Clinical Trials Logo

Clinical Trial Summary

This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be utilized to develop and conduct research on disease-specific protocols for adrenal disorders. The study targets patients with primary aldosteronism, pheochromocytoma, adrenal cancer, adrenal incidentalomas, and mild autonomous cortisol secretion. Registries for patients with adrenal diseases will be obtained from Seoul National University Hospital and Asan Medical Center, along with securing a common data model. The ultimate goal is to conduct research to generate clinical evidence for adrenal diseases using these resources.


Clinical Trial Description

The ultimate goal is to develop clinical evidence for unmet needs in adrenal gland diseases using real-world data, thereby contributing to the optimization of treatment guidelines. This involves: 1. Generating real-world healthcare data through prospective and retrospective registries specific to each adrenal disease. 2. Acquiring a common data model for adrenal diseases, applicable across both domestic and international multicenter settings. 3. Creating real-world data linked with hospital medical records and public data for each adrenal disease, utilizing anonymized information merging services. 4. Developing and conducting research based on prospective and retrospective registries, a common data model, and the utilization of public-medical data for different adrenal diseases. Study Design: Prospective and retrospective patient registries. Study Population: Patients with adrenal gland disorders, including primary aldosteronism, pheochromocytoma, adrenal cancer, adrenal incidentalomas, and mild autonomous cortisol secretion Research Methods: 1. Securing prospective and retrospective registries of patients with adrenal diseases. 2. Obtaining a common data model for adrenal diseases. 3. Utilizing the secured registries and common data model for multicenter studies to generate clinical evidence for adrenal diseases. 4. Linking public and medical data with the secured registries to further research in generating clinical evidence for adrenal diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06229405
Study type Observational [Patient Registry]
Source Seoul National University Hospital
Contact Jung Hee Kim, MD, PhD
Phone +82-10-2072-4839
Email jhee1@snu.ac.kr
Status Recruiting
Phase
Start date May 10, 2022
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Terminated NCT05948137 - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05069220 - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor Early Phase 1
Recruiting NCT06062082 - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting NCT04573816 - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Not yet recruiting NCT06045260 - "Receptor Radionuclide Therapy With 177Lu-DOTATOC Phase 2
Completed NCT00001147 - Blood Sampling for Neurochemical and Genetic Testing N/A
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00001229 - Diagnosis and Treatment of Pheochromocytoma N/A
Completed NCT01967576 - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03206060 - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Phase 2
Not yet recruiting NCT04788927 - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases